EPS Bio Technology Corp.
EPS Bio Technology Corp. manufactures and sells OEM/ODM blood glucose system in Taiwan. It also provides test strip; diabetic self-monitoring blood glucose systems under the EASYMAX and MDT2 BLE name; and wearable, and NFC and Bluetooth connectivity blood glucose monitors. The company was founded in 2006 and is headquartered in Hsinchu City, Taiwan.
EPS Bio Technology Corp. (4183) - Total Liabilities
Latest total liabilities as of December 2024: NT$237.34 Million TWD
Based on the latest financial reports, EPS Bio Technology Corp. (4183) has total liabilities worth NT$237.34 Million TWD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
EPS Bio Technology Corp. - Total Liabilities Trend (2019–2024)
This chart illustrates how EPS Bio Technology Corp.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
EPS Bio Technology Corp. Competitors by Total Liabilities
The table below lists competitors of EPS Bio Technology Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RPCG PCL F
F:R4Q
|
Germany | €5.37 Billion |
|
Kumpulan H & L High-Tech Bhd
KLSE:7033
|
Malaysia | RM37.63 Million |
|
MainStreetChamber Holdings Inc.
PINK:MSCH
|
USA | $94.38K |
|
Living Cell Technologies Limited
PINK:LVCLF
|
USA | $169.76K |
|
Fresh Grapes LLC
NYSE MKT:VINE
|
USA | $2.93 Million |
|
AB Panevezio Statybos Trestas
STU:YK3
|
Germany | €57.08 Million |
|
Forza Land Indonesia Tbk PT
JK:FORZ
|
Indonesia | Rp305.17 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down EPS Bio Technology Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EPS Bio Technology Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EPS Bio Technology Corp. (2019–2024)
The table below shows the annual total liabilities of EPS Bio Technology Corp. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$237.34 Million | +0.09% |
| 2023-12-31 | NT$237.12 Million | +8.08% |
| 2022-12-31 | NT$219.41 Million | -21.13% |
| 2021-12-31 | NT$278.18 Million | +16.97% |
| 2020-12-31 | NT$237.82 Million | -1.14% |
| 2019-12-31 | NT$240.55 Million | -- |